Introduction {#sec1-1}
============

The prognosis for patients with severe spinal cord damage is unfavorable. There have been many attempts to alter this prognosis with trials from different centers, but none of which have reliably altered the outcome.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] In the past few years, it has been found that transplantation of stem cells (SCs) from a variety of sources plays a positive part in the revival of neural tissue in cases of spinal cord injury (SCI).\[[@ref10][@ref11][@ref12]\] In SCI, the main purpose of applying SC transplantation is to restore impaired neuronal tissue and achieve better neurological function.\[[@ref65][@ref66]\] The effectiveness of SC therapy in the context of animal experiments has received great recognitions.\[[@ref1][@ref14][@ref15][@ref16][@ref17]\] The safety of this therapy has also been partially ascertained.\[[@ref4]\] The fact that in few clinical trials,\[[@ref5][@ref6][@ref13]\] neurological function was observed to be partially restored, has generated optimism about its role in SCI. Based on current research conducted on the mechanism of SC transplantation, there are indications that transplanted cells have survivability in the injured area, and they ramify into different forms of nerve cells, including neurons, astrocytes, and oligodendrocytes.\[[@ref7][@ref18]\] Furthermore, they also play a part in the revival of axons and remyelination,\[[@ref19][@ref20]\] neovascularization,\[[@ref21][@ref22][@ref23]\] neurotrophic impact\[[@ref15][@ref24][@ref25][@ref26][@ref27]\] as well as regulation of local inflammation and directed migration of endogenous neural SCs.\[[@ref28]\] It has been proven in research studies\[[@ref8][@ref10][@ref12][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37]\] that autologous bone marrow mesenchymal SCs (BM-MSCs) therapy in the case of traumatic SCI sufferers is safe in the long term. Unlike embryonic SCs, it is not ethically contentious to use autologous BM-MSCs. Moreover, given its autologous source, there is no cause for concern about immune rejection.\[[@ref6]\] Our study also involved the use of autologous SC but derived from the peripheral circulation rather than directly from BM. We used autologous hematopoietic SCs (HSCs) and PRP to avoid any possible alloimmune or sensitization reactions to the patient which might occur after usage of SCs or PRP from different sources. Besides, easy harvesting of autologous SCs will facilitate the application of this spinal cord repair method to many candidate patients. In addition, from our experience, the HSCs are multipotent cells which have the potential capacity to differentiate into many other types of cells. This latter function of HSCs might help in our opinion in regeneration and repair of the damaged spinal cord cells.

We have performed a clinical trial with the purpose of establishing how safe and potentially effective the autologous HSCs transplantation is. In this, we employed platelet-rich protein (PRP)\[[@ref39][@ref40]\] as a biological scaffold to hold the SCs *in situ*. PRP is a bioaggregate that is composed of growth factors, including transforming growth factor (TGF-β), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and basic fibroblast growth factor (bFGF).

Clinical trial design {#sec2-1}
---------------------

A team was formed at King Fahd University Hospital, Al Khobar, Saudi Arabia, to investigate the study of the cases of severe SCI and the treatment option of using SCs.

The team is composed of neurosurgeons, a neurophysiologist and neurologist, SCs specialist, and independent team (internal medicine) to closely examine and monitor the patient\'s progress before and after surgery. A protocol was written and submitted to the hospital administration for approval which was obtained on November 26, 2012.

The decision was made, not to propose the treatment to any patient, but to consider the cases who request this type of treatment.

Patient selection {#sec2-2}
-----------------

Each case was discussed within the treating team and with the hospital administration for approval.

Inclusion criteria {#sec2-3}
------------------

Age: \<60 years oldGender: Both male and femaleClinical evidence of severe SCI: The patient may be quadriplegic or paraplegic, with loss of sphincter control, and a clear sensory level. The patient must have exhausted every available methods of treatment with no improvementRadiological evidence of the injury: Well documented by magnetic resonance imaging (MRI)Spontaneous recovery: The patient\'s condition did not show any significant improvement since the traumaComorbidities: No concomitant systemic diseaseThe patient and his/her family should request the surgery and sign informed consent and attend several meetings to discuss this option of treatment.

Exclusion criteria {#sec2-4}
------------------

Evidence for clinical (motor and sensory) and/or electromyography (EMG) improvement in spinal cord functions since the original onset of SCIMinimal neurological impairmentMajor impairment of respiratory, cardiac, hepatic, or other systemic functionsBed sores.

Four patients in the trial included 3 males and 1 female, aged 21--51 years, treated in between the period of February--December 2013, and were followed up for 2--3 years. The period since their injury ranged from 4 to 180 months. Neurological levels of enrolled patients were between C6 and T12.

Ethical considerations {#sec2-5}
----------------------

To follow the ethical code, the following steps were taken:

The protocol to start the project of SCs therapy for severely injured spinal cord patients was submitted to the hospital board for approval. The approval was obtained for each caseAll of the patients enrolled in the study requested the treatment. No one was offered the treatment without requesting itPotential cases were studied carefully, and the selected cases were submitted case-by-case to the hospital authorities for approvalMeetings were conducted between the treating team and every patient and their families to explain all the facts related to this method of treatmentThe patient or a family member signed a special consent to show that they understand that the method was experimental and they accepted the consequences or side effects due to the procedureOn the night before surgery, the head of the team (the first author of this paper) went to the patient to ask him/her if he would like to change his/her opinion and cancel the case.

Surgical techniques, isolation, preparation, and transplantation of stem cells {#sec2-6}
------------------------------------------------------------------------------

### Isolation {#sec3-1}

After signing informed consent, G-CSF (Neupogen^®^-FDA approved) was given to the patient as a daily subcutaneous injection (10 μg/kg body weight) for 5 days to increase the SCs number in the blood stream. It stimulates the BM to produce a large number of hematopoietic and progenitor SCs and mobilizes them into the peripheral blood stream afterward. At the 5^th^ day after treatment (day of the operation), blood extraction was done and the mononuclear cell-rich leukapheresis product was extracted out of the sample using COBE® Spectra Apheresis System MNC which used continuous flow centrifugal technology. Extraction of CD34+ cells (hematopoietic progenitor cells) collected from peripheral blood cells was carried out using a Haemonetics MCS + cell separator machine and the final product of SCs was about 60 ml in volume. A trained nurse was present for taking care of the patients during the procedure to ensure their comfort and safety. The SCs were collected while the patients were in the operation room just immediately before spinal cord repair surgery.

The bag of collected SCs was left for 4 h to settle down. The buffy coat rich in SCs was obvious in the interface between plasma and red blood cells. Twenty milliliters of the supernatant plasma was withdrawn and discarded to further enrich the percentage of SCs in the final product bag. After proper mixing, 4 ml of the final SCs product was withdrawn using a sterile syringe.

### Preparation {#sec3-2}

The mainstay of this study is the preparation of platelet-rich protein (PRP) and coated fibrin to be used at the site of SCI with the SCs. Its purpose is to provide a three-dimensional (3D) scaffold capable of giving structural support and releasing endogenous growth factors which may enhance the function of the SCs and more importantly, to permanently patch the defected area. PRP is a bioaggregate that is composed of growth factors, including TGF-β, PDGF, VEGF, IGF, and bFGF.\[[@ref36][@ref47]\] It was prepared by extracting 20 ml of autologous peripheral blood from the third opened vein. It was transported to a Vivostat Machine (which is commercially available) for double centrifugation to separate the PRP aliquot from platelet-poor plasma and red blood cells. Afterward, PRP was prepared with fibrinogen to form a fibrin gel by adding calcium and thrombin. PRP was prepared in OR by aspirating 4 ml blood and processed in FACSCalibur flow cytometry machine (Atlanta, USA) to take 2.8 × 10^6^ in 1 ml and placed in the injured spine.

### Flow cytometric CD34+ HSC enumeration {#sec3-3}

Viable peripheral blood CD34^+^ cell counts were performed using a single-platform method \[[Figure 3](#F3){ref-type="fig"}\] using a FACSCalibur flow cytometer (BD, San Jose, CA). In brief, two samples were withdrawn from the final SCs' product bag. One sample was used for a complete blood count and the second one for immunophenotyping of the CD34+ cell count. A volume of 100 μL of SCs' bag was incubated with 10 μL of CD45 FITC (clone J33; Immunotech, Marseille, France), 10 μL of CD34 PE (Immunotech clone 581), and 10 μL of 7AAD (Immunotech) for 15 min at room temperature in the dark. Red cells were lysed with ammonium chloride (Immunotech) for 10 min. An equal volume of well-mixed Flow-Count fluorospheres (Beckman Coulter, Fullerton, CA, USA) of known concentration was added, and data were acquired on the flow cytometer without washing. The collection bag CD34+ cell counts were calculated and reported. The CD-45dim (total leukocyte count) of the product bag was 68.1 × 10^3^/μL. The CD34+ cell count was 0.48% of the total leukocyte count.

A 1 ml of SC products was implanted into the spinal cord lesion; afterward, it contained an average 2.8 × 10^6^ CD34+ SC. According to our knowledge, there is no published consensus to date on the optimum dose of CD34+ SCs to be used for repair of the spinal cord injuries. However, in our trial, we adjusted the CD34+ cells' concentration to 2.8 × 10^6^/ml at the final HSC product bag. In our hands, the length and size of SCI lesions allowed for implanting only 1 ml of the SCs' product, followed by the addition of autologous PRP.

### Transplantation {#sec3-4}

In the operating room, there were 6 teams working simultaneously and in coordination:

Team to harvest SCsTeam to prepare autologous fibrin sealant and platelet-rich proteinAnesthesia teamWell-trained nurse and technician teamIntraoperative neurophysiological monitoring teamThe neurosurgical team.

Under general anesthesia, the patients were positioned in prone position and the level of severely damaged spinal cord was identified. A standard limited one-level laminectomy was performed at the selected level of interest. The dura was opened under microscope. The injured area of spinal cord was carefully dissected and meticulous neurolysis was performed. Most of scar tissues were removed and the injured part of the spinal cord was reconstructed to conform, as closely as possible, to normal shape of spinal cord. The prepared SCs in operating room were introduced to the central canal (1 ml contains 2.8 × 10^6^ cells in average, the number of cells varied from case to case). After that, 1 ml of prepared PRP was sprayed over the SCs in the central canal to form a scaffold to keep the SCs functioning in that area.\[[@ref1]\] The spray technique was used to cover the whole operating area and the SCs in 3D fashion. The dura was closed and the wound was closed in layers. Patients who had not been intubated before surgery were extubated immediately after the surgery and transferred to the regular ward.

Intraoperative neuromonitor {#sec2-7}
---------------------------

To monitor the structural integrity and function of the spinal cord during the procedure of transplantation, somatosensory evoked potentials were used because of their capability of being used under general anesthesia. Motor potentials were evoked with transcranial electrical stimulation of the motor cortex of the brain. Electrical stimulation was then performed with rectangular constant current impulses of 500 μs duration and intensities between 15 and 200 mA. Individual stimuli elicit D-waves \[[Figure 9](#F9){ref-type="fig"}\], which can be recorded directly from the spinal cord caudal to the site of surgery. Motor evoked potentials can be recorded and detected from either spinal cord or muscles. The potential was recorded from the caudal spinal cord through an epidural electrode and consists of a bi- or tri-phasic sharp discharge (direct or D-wave), followed by a series of polyphasic waves (indirect or I-wave).

Illustrative cases {#sec2-8}
------------------

### Case 1 {#sec3-5}

A 21-year-old male was a victim of road traffic accident (RTA). On admission, he exhibited paradoxical breathing, hypotension, low pulse rate, and low oxygen saturation. There was no evidence of head injury, pupils were normal, Glasgow Coma Scale was 15/15, cranial nerves were intact, and computed tomography (CT) brain was normal. He exhibited no movement in his lower limbs, and the power grade was assessed as 0. In the upper limbs, the only movement he was able to achieve was in the shoulders assessed as power grade 3. The sensory level was above the nipples. CT and MRI of cervical spine demonstrated ptosis of C6 over C7 with possible cord transection. Figure [1a](#F1){ref-type="fig"}--[e](#F1){ref-type="fig"} showed preoperative MRI (sagittal and axial cuts) showing severe spinal cord damaged, indicated by arrow at the level of C6--C7.

![(a-e) Preoperative magnetic resonance imaging of Case 1 (sagittal and axial cuts) showed severe spinal cord damaged, which was indicated by arrow at the level of C6--C7](AJNS-12-681-g001){#F1}

Two days after admission, the patient underwent anterior decompression and fixation of C6--C7 by plates and screws. Following the operation, there was no evidence of improvement and the patient remained intubated and quadriplegic, receiving a tracheostomy 15 days later. After a further 10 months, with no improvement, the patient underwent reconstruction of the spinal cord with SC and PRP. Figure [2a](#F2){ref-type="fig"}--[c](#F2){ref-type="fig"} showed intraoperative reconstruction of the spinal cord at level C6--C7 and administration of SCs and PRP forming biological scaffold (1 ml contains 2.8 × 10^6^ Cells) as seen in [Figure 3](#F3){ref-type="fig"}.

![(a) Intraoperative view showed subdural thick scars and arachnoid cyst. (b) The spinal cord is reconstructed after the dissection. (c) The platelet-rich fibrin + stem cells in place at the end of surgery](AJNS-12-681-g002){#F2}

![Number of successfully obtained stem cells 2.8 × 10^6^/ml](AJNS-12-681-g003){#F3}

### Follow-up {#sec3-6}

The patient tolerated the procedure well. Six days following surgery, he was extubated and was breathing spontaneously for the first time since the RTA. Ten days later, he began to talk. Elbows, hands, and left lower limb gradually gained sensation. Movement was evident in both upper limbs. The patient reported sensation in both lower limbs 20 days postoperatively but inconsistent in the right lower limb. At 15 days further, movement was evident the left leg. Three months postsurgery, he was able to move both upper limbs and the left lower limb and gained pin-prick (PP) sensation in his upper limbs, body, and left lower limb. Sensation in the right lower limb was left inconsistent. Cervical MRI showed the biological scaffold remained in place, [Figure 4](#F4){ref-type="fig"}.

![(a-d) Three-month postoperative showed the reconstruction of the spinal cord and the biological PRP scaffold in place (indicated by arrows)](AJNS-12-681-g004){#F4}

Attempts for assisted standing at 6 months were unsuccessful. However, at 10 months, he succeeded and has progressed to being able to take a few steps.

Electromyogram (EMG) follow-up showed improvement both in motor and sensory functions.

### Case 2 {#sec3-7}

A 51-year-old woman presented with a 15-year history of dense paraplegia and uncontrolled sphincter, following RTA. Spinal cord transection at level D7--D8 and D11--D12 was demonstrated by physical examination and MRI. Figure [5a](#F5){ref-type="fig"}--[c](#F5){ref-type="fig"} showed transection of the spinal cord at level D10-D11. The patient was operated and scar tissues was removed and the pia was scrapped out, dissected away and the spinal cord was reconstructed. 2.8x106 /ml of autologous hematopoietic stem cells were prepared and injected in the reconstructed central canal, [Figure 6](#F6){ref-type="fig"}. PRP were injected over the stem cells to keep the cells in place in the reconstructed spinal canal [Figure 7](#F7){ref-type="fig"}.

![(a) Magnetic resonance imaging - sagittal cuts of the dorsal spine of case 2 showed transection of the spinal cord at the level of D10--D11. (b) Magnetic resonance imaging myelogram showed spinal cord transaction at the level of D10--D11. (c) Magnetic resonance imaging - axial cuts of D10 demonstrated severely damaged and transected spinal cord](AJNS-12-681-g005){#F5}

![Number of cells 2.8 × 10^6^/ml (cytometric analysis)](AJNS-12-681-g006){#F6}

![(a) Scars and scattered pieces of the spinal cord as seen under surgical microscope at the beginning of surgery. (b) Reconstruction of the spinal cord. (c) At the end of surgery, PRP (biological scaffold) + stem cells in place, inside, and surrounds the damaged part of the spinal cord](AJNS-12-681-g007){#F7}

### Follow-up {#sec3-8}

The patient tolerated the procedure very well. Two weeks later, the patient stated that she started to feel some sensation in the lower limbs, which is not convincing. Twelve months postoperatively, no movement was seen; PP and touch, vibration, and position sensation were not consistent. Despite the clinical findings, the patient said that she could feel that she had legs for the first time in 15 years. EMG follow-up showed no marked changes following surgery. [Figure 8](#F8){ref-type="fig"} showed the biological scaffold remained in place.

![(a) Postoperative magnetic resonance imaging cuts showed reconstruction of the spinal cord and PRP scaffold + stem cells 6 months later after surgery. (b) Postoperative magnetic resonance imaging cuts showed reconstruction of the spinal cord and PRP scaffold + stem cells 6 months later after surgery (axial cuts)](AJNS-12-681-g008){#F8}

Statistical evaluation {#sec2-9}
----------------------

Data are presented as mean ± standard deviation values. To compare data, we evaluated for statistical significance using two-way ANOVA with a *post hoc* Tukey *t*-test. In all analyses, a *P* \< 0.05 was considered statistically significant.

Results {#sec1-2}
=======

Flow cytometric analysis {#sec2-10}
------------------------

Two samples were withdrawn from the final SCs' product bag. One sample was used for a complete blood count and the second one for immunophenotyping of the CD34+ cell count. A FACSCalibur flow cytometry machine (Atlanta, USA) was used to assess the number of the CD34+ count in relation to the CD-45dim count. The CD-45dim (total leukocyte count) of the product bag was 68.1 × 10^3^/μl. The CD34+ cell count was 0.48% of the total leukocyte count. Regarding the 4 ml of SC products implanted into the spinal cord lesion afterward, it contained an average total of 2.8 × 10^6^ CD34+ SCs with a concentration of approximately 700 × 10^3^/ml.

Clinical outcome {#sec2-11}
----------------

The follow-up of these patients revealed several facts:

None of the patients developed any complication of the surgery or use of SCs for over 2--3 years. The patient\'s condition never deteriorated in any meansAll patients showed a significant improvement in their psychological status as they felt that they have tried all that is possible and had learned to accept their statusOnly one patient, the youngest one operated within 10 months showed marked motor and sensory improvingOne patient claimed gaining of sensationTwo patients did not show any improvement at allDelta waves seemed to be very important intraoperative monitorPRP proved to be very successful to keep SCs in the chosen place and functioned as biological scaffold avoiding possible complications and side effects of using artificial scaffolds.

[Table 1](#T1){ref-type="table"} American Spinal Injury Association scores of the cases involved before the intervention can be shown. In the treatment group, changes in ASIA Impairment Scale grade were observed in three patients with an improvement from A to B in two patients and from A to C in one patient as shown in the [Table 2](#T2){ref-type="table"} at 6 months period.

###### 

American Spinal Injury Association scores of the cases involved before the intervention

![](AJNS-12-681-g009)

###### 

Comparison of American Spinal Injury Association scores before and after the intervention (6 months period)

![](AJNS-12-681-g010)

Electrophysiological findings {#sec2-12}
-----------------------------

Intraoperative neurophysiologic monitoring (IONM) was used to detect early neurophysiological deterioration before being irreversible. It is uncommon to use IONM to detect early improvement in neurophysiological function; however, in our case, we did. We detected obvious changes in the amplitude of D-waves before and after SC implantation as can be shown in [Figure 9](#F9){ref-type="fig"}. There was an approximately 50% increase in amplitude of the D-wave after SC implantation and closing the spinal cord dura.

![D-wave recorded from the spinal epidural space intraoperative. Notice the baseline (thick red arrows). Notice the D-wave amplitude differences (yellow stars). (a) Before stem cell implantation. (b) After stem cell implantation](AJNS-12-681-g011){#F9}

Discussion {#sec1-3}
==========

Although laboratory results for the potential use of SCs in differing CNS problems seemed to be promising, patient trials at different centers have produced widely differing results.\[[@ref1][@ref65]\] There are serious scientific and ethical issues faced when transferring such successful laboratory experiments to clinical patient care. These problems include no general consensus about the use of SCs; no agreement about the number of cells that should be used; the method to obtain SCs varies greatly from center to center; the method of implantation or use is not agreed upon; the ideal time for use and the outcome of the techniques. Therefore, it is very important to report and record every trial and make the details and results of such trials available for world neuroscience researchers and neurosurgeons.

We present a novel method for transplanting SCs into severely damaged spinal cords. The concepts of our methods are careful and meticulous microdissection of the injured spinal area to remove any scar or necrotic tissue; use of the remaining, possibly functioning parts of the damaged spinal cord to reconstruct a spinal cord; use of hematopoietic autologous SCs, simultaneously with autologous platelet-rich protein (PRP) and fibrin sealant, both prepared on site, to possibly restore the functions of the spinal cord.

PRP has been used recently for treatment of diabetic foot and improves fat grafting, plastic surgery, dental surgery, and other fields.\[[@ref39][@ref40][@ref41][@ref42][@ref43][@ref44][@ref45][@ref46]\]

As far as we know, we are the first to use PRP and fibrin sealant along with autologous SCs to treat severe SCI. The principles of use are for reconstruction of the spinal cord and to function as autologous biological 3-D scaffold to contain and maintain the implanted SCs. The fibrin sealant and PRP may enhance the functions of SCs as PRP has the capability to release endogenous growth factors.\[[@ref44][@ref45][@ref46]\] Platelet-rich protein is rich in growth factor including TGF-β, PDGF, VEGF, IGF, and bFGF.\[[@ref40][@ref44][@ref46]\] PRP is considered as a bioaggregate of growth factors.\[[@ref39][@ref40]\]

A SCI is complex, involving different kinds of damage to different types of cells.\[[@ref47]\] The environment of the spinal cord changes drastically during the first few weeks after injury (immune cells flow in, toxic substances are released, a scar is formed). A combination of therapies is needed, acting at the appropriate time and on the correct targets.\[[@ref67][@ref68]\] Studies in animals have shown that a transplantation of SCs or stem cell-derived cells may contribute to spinal cord repair by replacing the nerve cells that have died as a result of the injury; generating new supporting cells that will reform the insulating nerve sheath (myelin) and act as a bridge across the injury to stimulate regrowth of damaged axons; protecting the cells at the injury site from further damage by releasing protective substances such as growth factors and soaking up toxins such as free radicals, when introduced into the spinal cord shortly after injury; and preventing spread of the injury by suppressing the damaging inflammation that can occur after injury.\[[@ref69]\]

Neuroscientists worldwide have not reached a consensus to answer dozens of questions on the use of SCs in clinical practice. We feel that our study is able to answer some of these questions, specifically.

The method to obtain active stem cells {#sec2-13}
--------------------------------------

Pluripotent SCs from BM or peripheral blood, the latter SCs have been used in our current study, may have therapeutic promise for SCI.\[[@ref48][@ref49]\] Although still debated,\[[@ref31]\] these particular adult SCs have been shown to differentiate into bone, fat, tendon, and cartilage cells.\[[@ref50]\] It has been published that these cells can also transdifferentiate *in vitro* into liver,\[[@ref51]\] skeletal,\[[@ref28][@ref52]\] and cardiac muscle\[[@ref22][@ref45]\] cells and into central nervous system cells.\[[@ref12][@ref53][@ref54][@ref55]\] Many medical fields are exploring MSCs, for instance, for repair of the heart after myocardial infarction,\[[@ref56][@ref57]\] osteogenesis imperfecta in orthopedics,\[[@ref58][@ref59]\] organogenesis in internal medicine,\[[@ref60][@ref61]\] intervertebral disk disease in neurosurgery,\[[@ref62][@ref63]\] and stroke/neurodegenerative diseases in neurology.\[[@ref54][@ref64]\]

How to control and direct stem cells to function in the right place? {#sec2-14}
--------------------------------------------------------------------

Combining the implant with PRP and a fibrin patch produces the desired result (fixing the SC in place) and function as biological scaffold.

How to monitor the procedure intraoperatively? {#sec2-15}
----------------------------------------------

IONM is used to detect early neurophysiological deterioration before being irreversible. It is uncommon to use IONM to detect early improvement in neurophysiological function; however, in our case, we did it. We detected obvious changes in the amplitude of D-waves before and after SC implantation \[[Figure 9](#F9){ref-type="fig"}\]. There was approximately 50% increase in the D-wave amplitude after SC implantation and closing the spinal cord dura.

What is the suggested technique for implantation? {#sec2-16}
-------------------------------------------------

Our study demonstrates that resection of necrotic tissue at the site with direct implantation can produce a successful outcome. Of the four patients enrolled in the study, one showed marked improvement following the procedure.

Many questions remained unanswered in our study. These include the number of cells required (dose); how to enhance the differentiation of SCs into neural cells; how to cross the scar and promote penetration and communication with the healthy parts of the spinal cord; how to avoid the immunological rejection of SCs; what is the timescale for achieving optimum results; how to best monitor the patient postoperatively; and what are the possible complications and side effects.

Ethical dilemma {#sec2-17}
---------------

Addressing and discussing the ethical use of SCs in the treatment of paraplegic or quadriplegic patients due to severe SCI are not simple. It involves many issues to be covered and addressed, including the perspective of the patient, the patient\'s family, the neurosurgeon, and the neuroscientist. Media coverage of SC use and possible litigation arising from it should also be addressed.

The basic and fundamental elements of bioethics are autonomy, beneficence, nonmaleficence, justice, dignity, truthfulness, and honesty. All these elements should be considered when discussing the ethical dilemma of using SCs in the management of severely injured spinal cord patients.

Conclusion {#sec1-4}
==========

Our experience steps forward in the long road for proper use of SCs transplant.

Achieved points:

Ability to mobilize SCs and obtain large number of cells from the peripheral circulation of the same patientAbility to patch using PRP as a biological scaffold to reconstruct (anatomical reconstruction) the severely damaged spinal cord at different levelAbility to keep the SCs functioning in the chosen siteClinical results still premature to judge; however, no harm whatever was inflected of any patient.

There are several issues need to be solved such as: 1. To prove that SCs may restore the functions of damaged spinal cord. 2. What is the optimum number of cells needed to restore the functions. 3. To learn about the course of recovery after severe spinal cord injury. 4. The value and precision of intra operative monitors and post operative monitors.

We recommend multicenter cooperation and collaboration to solve the previous mentioned problems. Focused meetings between neurosurgeons and neuroscientists should be encouraged and welcomed to answer the above-mentioned questions.
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